Navigation Links
PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
Date:3/20/2008

econd generation anthrax vaccine that offers the potential for improved safety and convenience," said Mr. Wright. "We believe Avecia's vaccine is well positioned to meet this requirement, as it is a highly purified recombinant form of a single protein -- protective antigen (PA), which is produced using standard biotechnology processes. In preclinical and clinical studies the vaccine has been shown to produce a vaccine-induced antibody response and was safe and well tolerated. If these results are confirmed in future studies, we believe this vaccine could prove to be a superior choice for procurement in the Strategic National Stockpile for civilian defense against anthrax threats."

Conference Call and Webcast

PharmAthene management will be hosting a conference call beginning at 4:30 pm Eastern Time today, Thursday, March 20, 2008, to discuss the Avecia deal in addition to the Company's year-end 2007 results. The dial-in number within the United States is 800-561-2813. The dial-in number for international callers is 617-614-3529. The participant passcode is 25398564.

A replay of the conference call will be available for 30 days, beginning at approximately 6:30 pm Eastern Time Thursday, March 20, 2008 until approximately 11:50 pm Eastern Time April 17, 2008. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 99739488.

The conference call will also be webcast and can be accessed from the company's website at http://www.pharmathene.com. A link to the webcast may be found on both the Home Page and also under the Investor Relations section of the website. The webcast will be available for 30 days, or until approximately Thursday, April 17, 2008.

About PharmAthene, Inc.

PharmAthene (Amex:

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
2. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
3. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
4. PharmAthene to Present at the BIO CEO & Investor Conference 2008
5. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
6. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
7. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
10. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
11. Corgenix Signs Technology Licensing Agreement With Japanese Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- Research and Markets has announced the addition ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... used to determine the size of a particle in a ... analyze the size of particles as it can affect the ... to determine the behavior and nature of a material, and ...
(Date:7/26/2014)... Canada Endoscopy Visualization Systems Market ... the Canada Endoscopy Visualization Systems market. The report ... (in units) and average prices (in US dollars) ... Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy Visualization ... . , The report also provides company shares ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... new study by researchers from the University of ... nanosystems function, unlocking the potential to create new ... which has been published in the prestigious academic ... novel laser technique to examine in rich detail ... small cluster containing an acetylene molecule and a ...
Breaking Biology Technology:Global Particle Size Analysis Market 2014-2018 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3
... SAN DIEGO, Aug. 25 NexBio, Inc. announced today ... Human Lung Tissues" in the September, 2009 issue of the ... DAS181 (Fludase ((R)) ) is an investigational drug ... (e.g. Tamiflu ((R)) ), which target the virus, DAS181 works ...
... 25 Peptimmune, Inc., a privately held biotechnology company, ... the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in ... is a novel peptide copolymer for the treatment of ... The Phase Ib multiple-ascending dose, double-blind, placebo-controlled, ...
... - Medicago Inc. (TSX-V: MDG) a biotechnology company ... based on proprietary manufacturing technologies and Virus-Like Particles ... from Health Canada to commence a Phase I ... vaccine ("H5N1 vaccine"). Enrollment of volunteers is now ...
Cached Biology Technology:NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 2NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 3NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 4Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 2Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 3
(Date:7/27/2014)... date, researchers from the U.K. provide national, regional, and ... (HCV). Findings published in Hepatology, a journal of the ... that genotype 1 is the most prevalent worldwide, with ... in East Asia. Genotype 3, at just over 54 ... genotypes 2, 4, 6, and 5. , Despite ...
(Date:7/27/2014)... Microorganisms like bacteria and fungi can evade treatment by ... antifungal drugs. These permanent mutations were once thought to ... Now a new study has shown that microorganisms can ... as epimutations -- to gain the benefits of drug ... was discovered in a fungus called Mucor circinelloides, it ...
(Date:7/27/2014)... have found that targeting a molecule in blood vessels ... research published in Nature today (Sunday)., The ... University of London, have found that a molecule, called ... itself after chemotherapy or radiotherapy, which kill cancer cells ... blood vessels that grew in melanoma or lung cancer ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2
... the Pediatric Study of Hepatitis C (PEDS-C) trial reveals ... C (HCV) display significant changes in height, weight, body ... the August issue of Hepatology , a journal ... Diseases, indicate that most growth-related side effects are reversible ...
... Clemson University researchers are teaming up with Coastal ... of sensors along the Savannah River to gather data ... will collect and transmit real-time information about the quality ... Intelligent River project leaders Gene Eidson, director of Clemson,s ...
... Lab on a chip (LOC) devicesmicrochip-size systems that can ... from a few microliters (millionth of a liter) to ... to one day revolutionize how laboratory tasks such as ... a recent paper* from the National Institute of Standards ...
Cached Biology News:Height, weight and BMI changes seen in children treated with peginterferon alpha for hepatitis C 2Clemson, Coastal Carolina universities to set hundreds of sensors in Savannah River 2NIST focuses on testing standards to support lab on a chip commercialization 2
...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... provides a simple and efficient means for ... lture using annexin V magnetic beads (MagBeads). ... protein with high affinity for phosphatidylseri ... simple and efficient means for isolation of ...
... Linkage: This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Biology Products: